Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C48H56N12.5Cl.Mn |
| Molecular Weight | 1033.242 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].CCN1C=C[N+](CC)=C1C2=C3[N-]C(C=C3)=C(C4=NC(C=C4)=C(C5=CC=C([N-]5)C(=C6C=CC2=N6)C7=[N+](CC)C=CN7CC)C8=[N+](CC)C=CN8CC)C9=[N+](CC)C=CN9CC
InChI
InChIKey=XMYHQLIAYLLEKT-UHFFFAOYSA-I
InChI=1S/C48H56N12.5ClH.Mn/c1-9-53-25-26-54(10-2)45(53)41-33-17-19-35(49-33)42(46-55(11-3)27-28-56(46)12-4)37-21-23-39(51-37)44(48-59(15-7)31-32-60(48)16-8)40-24-22-38(52-40)43(36-20-18-34(41)50-36)47-57(13-5)29-30-58(47)14-6;;;;;;/h17-32H,9-16H2,1-8H3;5*1H;/q+2;;;;;;+3/p-5
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Mn |
| Molecular Weight | 54.938045 |
| Charge | 3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C48H58N12 |
| Molecular Weight | 803.0545 |
| Charge | 4 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AEOL-10150 is a small-molecule antioxidant developed by Aeolus (formerly Incara) for potential subcutaneous treatment for amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, lung inflammation, and mucositis. Structurally, AEOL-10150 functions as a superoxide-dismutase mimic and contains metalloporphyrin moiety. AEOL-10150 possess high superoxide-dismutase activity as well as catalase-like activity and has the capacity to scavenge peroxynitrite and lipid peroxides. In 2017 Aeolus Pharmaceuticals has announced that the FDA has granted Fast Track designation to AEOL 10150 for the prevention of fatal respiratory failure among patients at risk for radiation pneumonitis following a radiological/nuclear incident sufficient to cause the Acute Radiation Syndrome.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:46:10 GMT 2025
by
admin
on
Tue Apr 01 16:46:10 GMT 2025
|
| Record UNII |
KPKO7W46E8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
176703
Created by
admin on Tue Apr 01 16:46:10 GMT 2025 , Edited by admin on Tue Apr 01 16:46:10 GMT 2025
|
||
|
FDA ORPHAN DRUG |
465414
Created by
admin on Tue Apr 01 16:46:10 GMT 2025 , Edited by admin on Tue Apr 01 16:46:10 GMT 2025
|
||
|
FDA ORPHAN DRUG |
354611
Created by
admin on Tue Apr 01 16:46:10 GMT 2025 , Edited by admin on Tue Apr 01 16:46:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10373834
Created by
admin on Tue Apr 01 16:46:10 GMT 2025 , Edited by admin on Tue Apr 01 16:46:10 GMT 2025
|
PRIMARY | |||
|
DB05874
Created by
admin on Tue Apr 01 16:46:10 GMT 2025 , Edited by admin on Tue Apr 01 16:46:10 GMT 2025
|
PRIMARY | |||
|
286475-30-7
Created by
admin on Tue Apr 01 16:46:10 GMT 2025 , Edited by admin on Tue Apr 01 16:46:10 GMT 2025
|
PRIMARY | |||
|
KPKO7W46E8
Created by
admin on Tue Apr 01 16:46:10 GMT 2025 , Edited by admin on Tue Apr 01 16:46:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
AEOL 10150, is being developed as a medical countermeasure for the pulmonary effects of Acute Radiation Syndrome (Lung-ARS) under a $118MM, 5 year contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. Efficacy has been demonstrated in Lung-ARS in both monkey and mouse studies with AEOL 10150 treated groups showing significantly reduced weight loss, inflammation, oxidative stress, lung damage and, most importantly, mortality. AEOL 10150 has also demonstrated efficacy in validated animal models for chlorine gas exposure, and sulfur mustard gas exposure.
|